Who is sponsoring NCT04831307?

NCT04831307 is sponsored by British Columbia Cancer Agency.

What condition does NCT04831307 study?

NCT04831307 studies Prostate Cancer, Prostatic Neoplasm, Prostatic Disease, Urogenital Neoplasms, Disease Attributes, Neoplasms.

What drugs are being tested in NCT04831307?

Interventions: [68Ga]Ga-HTK03149 PET/CT.

What is the status of NCT04831307?

NCT04831307 is currently UNKNOWN.

Last reviewed 2021-12-01 · How we verify

Evaluation of the in Vivo Biodistribution and Radiation Dosimetry of 68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical

NCT04831307 NA UNKNOWN

This is a preliminary evaluation of a radiotracer's biodistribution in human subjects. It is a prospective, single-centre, open-label, single group assignment interventional study. Prostate cancer is very common, and PSMA imaging is currently the most accurate means of localizing these tumours. The goal is to evaluate the biodistribution and safety of \[68Ga\]HTK03149 PET/CT for prostate cancer imaging.

Details

Lead sponsor	British Columbia Cancer Agency
Phase	NA
Status	UNKNOWN
Enrolment	10
Start date	2021-08-30
Completion	2022-08

Conditions

Prostate Cancer
Prostatic Neoplasm
Prostatic Disease
Urogenital Neoplasms
Disease Attributes
Neoplasms

Interventions

[68Ga]Ga-HTK03149 PET/CT

Primary outcomes

Biodistribution of 68Ga-HTK03149 PET/CT in human subjects — Up to 12 months
Evaluate the biodistribution of 68Ga-HTK03149 in human subjects, which will enable calculating the radiation dosimetry of this radiopharmaceutical. The efficacy parameters will be the following: Individual organ dose and effective dose measured in mSV/MBq. Descriptive statistics on normal organ and tumour uptake reported in standardized uptake values (SUV). Tumour/blood, tumour/liver, tumour/kidney and tumour/lung ratios will be reported.

Countries

Canada